Evidence Generation Evolved

By Colin Weller, VP, Product Management

The pharmaceutical industry faces a formidable challenge: on average, it takes 12 years and $3 billion to bring a new drug to market, with the FDA approving about 50 new therapies annually. This pace is insufficient to meet global healthcare needs and falls short of our future goal to help the industry produce ten times the number of treatments it currently does.

A major bottleneck is the lengthy clinical trial process, particularly Phase 3 studies, which can extend beyond three years. Compounding this issue is the difficulty in recruiting enough patients for these crucial studies, often adding up to two years to the already extensive timeline.

As leaders in clinical research, our mission is to transform the world by delivering more effective treatments to patients faster. We have made significant strides in shortening clinical trial timelines, reflecting our commitment to this vision.

Typically, a drug development program includes up to 15 individual studies, each requiring its own start-up phase. This results in deployment periods of three to six months per trial, creating significant delays during which no participants are recruited and no new data is generated. At Medable, we have successfully halved start-up times by leveraging innovative technology and processes, accelerating the path to new treatments.